NCT00672373

Extract of Ginkgo Biloba and Tardive Dyskinesia

A Double-Blind, Randomised, Parallel-Group Comparison of Extract of Ginkgo Biloba(EGB-761) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 157 (actual)
• Sponsor: Beijing HuiLongGuan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Extract of Ginkgo Biloba is effective in the treatment on Tardive dyskinesia

Detailed description

Tardive dyskinesia(TD) is a common complication of conventional antipsychotic treatment in subjects with schizophrenia. There is no established treatment for TD patients.This disorder remains a significant clinical problem for both patients and physicians for the foreseeable future.

Conditions

• Tardive Dyskinesia
• Schizophrenia

Interventions

Type	Name	Description
DRUG	Extract of Ginkgo Biloba (EGb-761 capsules)	EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.
DRUG	Placebo	Wheat flour placebo capsule,1 capsule tid, po,12 weeks

Timeline

• Start date: 2006-12-01
• Primary completion: 2007-05-01
• Completion: 2007-08-01
• First posted: 2008-05-06
• Last updated: 2008-05-06

Locations

1 site across 1 country: China